The researchers’ primary goal was to demonstrate that resveratrol treatment in patients with low-grade GI neuroendocrine tumors will significantly increase Notch1 activation in post-treatment tumor biopsy specimens when compared to pretreatment levels. The gene discussed is NOTCH1; the disease is neoplasm.